Tombari RJ

Institute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, California 95616, United States.

8 papers · ORCID

ArticleMDMA

R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.

Vargas MV, Hatzipantelis CJ, Dunlap LE +7

Europe PMC2026

ArticleLSD

Design, Synthesis, and In Vitro Characterization of a Tryptamine-Based Visible-Light Photoswitchable 5-HT2AR Ligand Showing Efficacy Preference for β-Arrestin over Mini-Gq.

Sink A, Pottie E, Carter SJ +7

Europe PMC2025

ArticleLSD

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential.

Tuck JR, Dunlap LE, Khatib YA +27

Europe PMC2025

ArticlePsychedelics

Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease.

Warren HT, Saeger HN, Tombari RJ +3

Europe PMC2024

ArticlePsychedelics

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors.

Vargas MV, Dunlap LE, Dong C +11

Europe PMC2023

ArticleKetamine

Developmental Neurotoxicity Screen of Psychedelics and Other Drugs of Abuse in Larval Zebrafish (Danio rerio).

Tombari RJ, Mundy PC, Morales KM +3

Europe PMC2023

ArticleIbogaine

A non-hallucinogenic psychedelic analogue with therapeutic potential.

Cameron LP, Tombari RJ, Lu J +26

Europe PMC2021

ArticleDMT

Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies.

Dunlap LE, Azinfar A, Ly C +9

Europe PMC2020

Tombari RJ

<i>R</i>-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.

Design, Synthesis, and In Vitro Characterization of a Tryptamine-Based Visible-Light Photoswitchable 5-HT<sub>2A</sub>R Ligand Showing Efficacy Preference for β-Arrestin over Mini-Gq.

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential.

Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease.

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors.

Developmental Neurotoxicity Screen of Psychedelics and Other Drugs of Abuse in Larval Zebrafish (<i>Danio rerio</i>).

A non-hallucinogenic psychedelic analogue with therapeutic potential.

Identification of Psychoplastogenic <i>N</i>,<i>N</i>-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies.

Tombari RJ

&lt;i&gt;R&lt;/i&gt;-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.

Design, Synthesis, and In Vitro Characterization of a Tryptamine-Based Visible-Light Photoswitchable 5-HT&lt;sub&gt;2A&lt;/sub&gt;R Ligand Showing Efficacy Preference for β-Arrestin over Mini-Gq.

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential.

Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease.

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors.

Developmental Neurotoxicity Screen of Psychedelics and Other Drugs of Abuse in Larval Zebrafish (<i>Danio rerio</i>).

A non-hallucinogenic psychedelic analogue with therapeutic potential.

Identification of Psychoplastogenic <i>N</i>,<i>N</i>-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies.

<i>R</i>-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.

Design, Synthesis, and In Vitro Characterization of a Tryptamine-Based Visible-Light Photoswitchable 5-HT<sub>2A</sub>R Ligand Showing Efficacy Preference for β-Arrestin over Mini-Gq.